Adaptin Bio (APTN) Profit After Tax (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Profit After Tax data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 90.04% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$5.7 million (down 68.64% YoY), and the FY2025 full-year result was -$5.2 million, down 65.49% from the prior year.
• Profit After Tax improved to -$1.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$34155.0 in Q4 2023 to a low of -$1.7 million in Q3 2025.
• A 4-year average of -$864846.8 and a median of -$856836.0 in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax slumped 2479.42% in 2024 and sank 51.29% in 2025, its largest moves.
• Tracing APTN's Profit After Tax over 4 years: stood at -$34155.0 in 2023, then tumbled by 2408.67% to -$856836.0 in 2024, then sank by 59.66% to -$1.4 million in 2025, then gained by 16.22% to -$1.1 million in 2026.
• Business Quant data shows APTN's Profit After Tax at -$1.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.7 million in Q3 2025.